Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives

Xiongwen Ran
Kai Yang
Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China

Abstract: Head and neck cancer (HNC) is a common malignant tumor, but traditional therapeutic methods have unsatisfactory curative effects and many complications occur. Hence, there is an urgent need to develop therapeutic methods that can elicit curative effects as well as low toxic and few side effects. With the development of cancer molecular biology and immunology, targeted therapy for immune checkpoints of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) has shown enormous development prospects for HNC treatment. Groundbreaking progress has been achieved in the treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). This review describes current treatment by PD-1- and PD-L1-targeted drugs for HNC.

Keywords: head and neck cancer, squamous cell carcinoma, programmed cell death 1, programmed cell death ligand 1, immunotherapy, immune checkpoint

Introduction

Head and neck cancer (HNC) is the eighth most common cancer worldwide. Approximately 90% of HNC is head and neck squamous cell carcinoma (HNSCC), with ~650,000 new cases reported annually worldwide.\(^1,2\) As a rule, HNC is divided into two subclasses: human papillomavirus positive (HPV+) and human papillomavirus negative (HPV−).\(^3\) HPV− HNC is caused mostly by tobacco smoking and alcoholism (75% of patients), and these patients have stronger resistance to treatment and a worse prognosis than HPV+ HNC patients.\(^2,8\)

Despite continuous development of conventional therapies such as surgery, radiotherapy, and chemotherapy, the 5-year survival of HNSCC is worse than that of other cancers. Since 1975, the 5-year relative survival for cancer of the oral cavity and pharynx has increased from 53% to 63%, whereas that of laryngeal cancer has decreased from 67% to 61%.\(^9,12\) In addition, conventional therapeutic methods can result in serious physiologic and psychological complications such as pain, infection, caries, distress, depression, or anxiety.\(^3,13\) Therefore, the development of new therapeutic methods of high curative value as well as low toxicity and side effects, especially for patients with advanced HNC, is needed.

Thanks to in-depth studies on the molecular biology and immunology of cancer, cancer immunotherapy has shown immense prospects for the development in HNSCC treatment. The effector arm of cancer immunotherapy is regulated by positive and negative co-signaling pathways or “immunologic checkpoints.” The checkpoints of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have
important roles in the formation of “immune privilege” regions, viral persistence, tumor development, and immune evasion.\textsuperscript{1,14,15} In 2016, the results of two milestone trials—an open-label, multicenter, Phase Ib trial (KEYNOTE-012) and a randomized, open-label, Phase III trial (CheckMate 141)\textsuperscript{16–18}—were announced. Those results facilitated pembrolizumab (MK-3475) and nivolumab (BMS-936558), which are antagonists of the PD-1/PD-L1 axis, to become the first molecular-targeted therapeutic drugs to be approved by the US Food and Drug Administration (FDA) for HNSCC. Later, the two drugs were compiled into clinical guidelines for HNSCC treatment in the National Comprehensive Cancer Network and became the fourth standard therapeutic method (after surgery, radiotherapy, and chemotherapy) for HNSCC.\textsuperscript{19} These observations suggest that molecular-targeted therapy for HNSCC may be entering a new era.

The current status of anti-PD-1/anti-PD-L1-targeted drugs in HNC treatment is summarized in this review. Also, a prospective evaluation of PD-1/PD-L1 molecular-targeted therapy is presented.

**Structural features of PD-1/PD-L1**

PD-1 is a member of the CD28/CTLA-4/ICOS costimulatory receptor family. PD-1 is a monomeric type-I surface transmembrane glycoprotein consisting of 268 amino acids. Its structure mainly comprises an extracellular region consisting of a higher signal sequence and immunoglobulin variable (IgV)-like structures, a hydrophobic transmembrane region, and an intracellular region. There are two independent tyrosine residues at the tail end in the intracellular region. The tyrosine residue at the amino end participates to constitute an immunoreceptor tyrosine-based inhibitory motif. The tyrosine residue at the hydroxyl end helps to constitute an immunoreceptor tyrosine-based switch motif (ITSM).\textsuperscript{20–22}

The PD-1 ligands termed PD-L1 and PD-L2 belong to the B7 superfamily, and the family members also include B7-1 (cluster of differentiation [CD]80), B7-2 (CD86), B7-H2, B7-H3, B7-H4, and B7-H6.\textsuperscript{14,23} The structures of PD-L1 and PD-L2 mainly comprise an extracellular region consisting of IgV-like structures in series and immunoglobulin constant region-like structures, a hydrophobic transmembrane region, and an intracellular region with a short cytoplasmic tail of unknown function.\textsuperscript{20,23} The affinity of the PD-1/PD-L1 extracellular region with PD-1 is lower than that of the PD-L2 extracellular region with PD-1. However, the PD-L1 extracellular region can also bind with the B7-A (CD80) extracellular region.\textsuperscript{14,20,23} PD-L2 is expressed only in activated macrophages and dendrites;\textsuperscript{20} hence, only few studies have been done on PD-L2. Therefore, the emphasis of this review is on PD-1 and PD-L1.

**Expression pattern and antitumor mechanism of PD-1/PD-L1 and their expression profile in HNSCC**

**Expression pattern of PD-1/PD-L1**

PD-1 is expressed on activated T cells after induction by a T-cell antigen receptor and cytokine receptor.\textsuperscript{20} PD-1 is also expressed at low levels on double-negative (CD4\textsuperscript{−}/CD8\textsuperscript{−}) T cells in the thymus, activated natural killer T cells, B cells, monocytes, and immature Langerhans’ cells.\textsuperscript{14,20,22} Transcription of PD-1 in T cells requires nuclear translocation of nuclear factor of activated T cells (NFAT) as well as binding of NFATc1 (NFAT2) to the PDCD1 promoter.\textsuperscript{20}

PD-L1 is expressed constitutively at low levels on antigen-presenting cells (APCs) and a wide variety of non-hematopoietic cell types, including vascular endothelial cells, pancreatic islet cells, and cells at sites of immune privilege (eg, placenta, testes, and eye).\textsuperscript{14,20,24} Inflammatory cytokines such as type I and type II interferons as well as tumor necrosis factor α and vascular endothelial growth factor can induce PD-L1 expression.\textsuperscript{20,24}

Tumor cells upregulate PD-L1 expression by four main mechanisms. The first mechanism is activation of the epidermal growth factor receptor (EGFR), mitogen-activated protein kinase, phosphoinositide 3-kinase (PI3K)-Akt or Janus kinase 2/signal transducer and activator of transcription 1 signaling pathways.\textsuperscript{20,26–28} Increased expression of STAT3 and hypoxia-inducible factor-1 transcription factors can upregulate the expression of PD-L1.\textsuperscript{25,29–31} The second mechanism is amplification of genes coding PD-L1 (9p24.1).\textsuperscript{26,29} The third mechanism is induction of the Epstein–Barr virus (EBV). Gastric cancer and EBV + nasopharyngeal carcinoma can result in high expression of PD-L1 even without amplification of the 9p24.1 gene.\textsuperscript{32,33} However, whether the HPV is positive in HNSCC is not correlated with PD-L1 expression;\textsuperscript{27,34} the final mechanism is epigenesis. Some microRNAs (miR-34a, miR-200, miR-513, and miR-570) have a negative correlation of the expression profile in HNSCC is not correlated with PD-L1 expression;\textsuperscript{27,34} the final mechanism is epigenesis. Some microRNAs (miR-34a, miR-200, miR-513, and miR-570) have a negative correlation with PD-L1 expression.\textsuperscript{20,35} Moreover, in the tumor microenvironment, the stimulatory effects of inflammatory factors can also induce PD-L1 expression, where interferon-γ is the most important stimulating factor.\textsuperscript{13,20,24,25,27}

**Antitumor mechanism of PD-1/PD-L1**

Complete activation of T cells is dependent upon the regulation of a “dual-signal” system. The first signal is derived from specific binding between a T-cell receptor and a major
histocompatibility complex class, namely, antigen recognition of T cells. The second signal arises from co-stimulating molecules, namely, the signal mediated by the interaction between APC-expressed co-stimulatory molecules and the corresponding receptor or ligand on the T-cell surface. For example, CD28/B7 is an important positive co-stimulating molecule. In addition to ensuring that T cells are not overstimulated, there are negative co-stimulatory molecules that regulate T cells, and they are mainly cytotoxic T-lymphocyte-associated protein 4 (CTLA4)-B7 signaling pathways and PD-1/PD-L1 signaling pathways. After PD-1 and PD-L1 bind with each other in activated T cells, tyrosine in the ITSM structural domain of PD-1 undergoes phosphorylation, which causes dephosphorylation of the downstream protein kinases Syk and PI3K. These actions lead to inhibition of the activation of downstream channels such as Akt and ERK. Finally, inhibition of the transcription and translation of genes and cytokines required by T-cell activation leads to the regulation of T-cell activity. After invasion by tumor cells, these signal channels are used to inhibit T-cell activation so as to evade attack by the immune system. At present, inhibitors of immune checkpoints have been studied, and the ones applied most extensively are CTLA-4, PD-1, and PD-L1 monoclonal antibodies. The anti-tumor effect is realized by the inhibition of the activity of immune checkpoints, blockade of immunosuppression in the tumor microenvironment, and reactivation of the immune response of T cells to the tumor (Figure 1).

Expression profile of PD-1/PD-L1 in HNSCC

Increased expression of PD-1/PD-L1 in the microenvironment of HNSCC is independent of HPV status. Yu et al undertook a meta-analysis of 18 data sets of gene expression

![Figure 1](image-url)
of HNCs and verified that CD274 (the gene encoding PD-L1) and CD279 (the gene encoding PD-1) DNA copy numbers, as well as the mRNA expression of these genes, was increased significantly in HNSCC ($P<0.05$). Also, through a comparative analysis of HNSCC and the normal mucosa, PD-1/ PD-L1 expression in cells was high in the microenvironment of HNSCC, but there was no obvious difference in HPV+ (n=12) or HPV− (n=74) subgroups.

In a tumor microenvironment, PD-L1 is expressed not only on relevant immune cells in the microenvironment but also on tumor cytomembranes and in the cytoplasm. Lyford-Pike et al$^4$ compared HPV-infected non-cancerous adult tonsil tissues with cancer tissues from HNSCC patients and verified that, at the cell level, localized expression of PD-L1 was within deep tonsillar crypts, the site of initial HPV infection, and the origin of HPV-HNSCC. PD-L1 in tumor cells was expressed mainly on membranes (cell surface) and partially in the cytoplasm.

**Clinical application of PD-1/PD-L1-targeted drugs for HNC treatment**

Currently, the PD-1/PD-L1-targeted drugs used in HNC treatment are pembrolizumab, nivolumab, and durvalumab (Table 1).

**PD-1-targeted drugs**

The main PD-1-targeted drugs used to treat HNSCC are pembrolizumab and nivolumab, both of which are humanized PD-1-inhibiting IgG4 monoclonal antibodies with high specificity.$^{16-18}$ They have been used for the treatment of patients with recurrent/metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. Also, pembrolizumab has certain effects on adult patients with salivary gland carcinomas at an advanced stage.$^{38}$

**Pembrolizumab**

Seiwert et al$^{16}$ used pembrolizumab to treat 60 patients with recurrent/metastatic HNSCC. All the patients had PD-L1 expression in tumor cells of ≥1%, whereas 23 cases (38%) were HPV+ and 37 cases (62%) were HPV−. Pembrolizumab (10 mg/kg body weight, intravenous [iv]) was administered once every 2 weeks for 24 months. Median duration of follow-up was 14 (interquartile range [IQR] 4–14) months. The overall response rate (ORR) was 18%, whereas the response rate of HPV+ was 25% and that of HPV− was 14%.

The median progression-free survival (PFS) was 2 months. The median overall survival (OS) was 13 months. Thirty-eight cases experienced treatment-related adverse events (63%), mainly fatigue, pruritus, nausea, reduced appetite, and rash. There were no treatment-related deaths.

Chow et al$^{17}$ used pembrolizumab to treat 132 adult patients with recurrent/metastatic HNSCC. Of these, 28 cases (21%) were HPV+ and 104 cases (71%) were HPV−. Pembrolizumab (200 mg, iv) was administered once every 3 weeks for 24 months. The median duration of follow-up was 9 (IQR 3–11) months. The median overall survival (OS) was 13 months. Thirty-eight cases experienced treatment-related adverse events (63%), mainly fatigue, pruritus, nausea, reduced appetite, and rash. There were no treatment-related deaths.

**Table 1 Efficacy and safety of PD-1/PD-L1-targeted drugs in HNC treatment**

<table>
<thead>
<tr>
<th>Monoclonal antibody</th>
<th>Phase</th>
<th>Patient no</th>
<th>ORR, no (%)</th>
<th>PFS (months)</th>
<th>OS (months)</th>
<th>AE, no (%)</th>
<th>AE ≥ 3, no (%)</th>
<th>DrD no</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pembrolizumab</td>
<td>I</td>
<td>60</td>
<td>8 (17.8%)</td>
<td>2</td>
<td>13</td>
<td>38 (63%)</td>
<td>10 (17%)</td>
<td>0</td>
</tr>
<tr>
<td>(MK-3475)$^a$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>I</td>
<td>132</td>
<td>24 (18.2%)</td>
<td>3</td>
<td>8</td>
<td>82 (62%)</td>
<td>12 (9%)</td>
<td>0</td>
</tr>
<tr>
<td>(MK-3475)$^a$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>II</td>
<td>50</td>
<td>9 (18.0%)</td>
<td>–</td>
<td>–</td>
<td>35 (70%)</td>
<td>6 (12%)</td>
<td>1</td>
</tr>
<tr>
<td>(MK-3475)$^a$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>II</td>
<td>26</td>
<td>3 (11.5%)</td>
<td>–</td>
<td>–</td>
<td>22 (84.6%)</td>
<td>3 (11.5%)</td>
<td>1</td>
</tr>
<tr>
<td>(MK-3475)$^a$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Durvalumab</td>
<td>I/II</td>
<td>62</td>
<td>6 (11.7%)</td>
<td>–</td>
<td>–</td>
<td>60%</td>
<td>7%</td>
<td>0</td>
</tr>
<tr>
<td>(MEDI4736)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Durvalumab</td>
<td>I</td>
<td>50</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>39%</td>
<td>5%</td>
<td>0</td>
</tr>
<tr>
<td>(MEDI4736)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Durvalumab</td>
<td>I</td>
<td>105</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>33%</td>
<td>7%</td>
<td>–</td>
</tr>
<tr>
<td>(MEDI4736)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nivolumab</td>
<td>III</td>
<td>240</td>
<td>32 (13.3%)</td>
<td>2.0</td>
<td>7.5</td>
<td>139 (58.9%)</td>
<td>31 (13.1%)</td>
<td>2</td>
</tr>
<tr>
<td>(BMS-936558)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard therapy</td>
<td>III</td>
<td>121</td>
<td>7 (5.8%)</td>
<td>2.3</td>
<td>5.1</td>
<td>86 (77.5%)</td>
<td>39 (35.1%)</td>
<td>1</td>
</tr>
</tbody>
</table>

**Notes:** $^–$ indicates no mention in the original literature. $^a$Pembrolizumab (10 mg/kg, intravenous) once every 2 weeks. $^b$Pembrolizumab (200 mg, intravenous) once every 3 weeks.

**Abbreviations:** HNC, head and neck cancer; ORR, overall response rate; PFS, progression-free survival; OS, overall survival; AE, adverse events; DrD, drug-related death.
rate of HPV+ was 32% and that of HPV− was 14%. The median PFS was 2 months. The median OS was 8 months. Also, 82 cases (62%) experienced treatment-related adverse events, mainly fatigue, hypothyroidism, and reduced appetite. There were no treatment-related deaths.

Bauml et al89 used pembrolizumab to treat 50 patients with recurrent/metastatic HNSCC after the failure of platinum-based treatment and cetuximab. Pembrolizumab (200 mg, iv) was administered once every 3 weeks for 24 months. The median duration of follow-up was 6.8 months. The ORR was 18%; the partial response rate (PRR) was 18% and the stable disease rate was 18%. Also, 35 cases (70%) experienced treatment-related adverse events, mainly specific immunologic diseases, hypothyroidism, and pneumonia. Two patients (4%) discontinued treatment because of treatment-related adverse events, and 1 patient (2%) died of treatment-related adverse events. Their clinical trial showed that pembrolizumab also had high antitumor activity and few toxic and side effects for patients with recurrent/metastatic HNSCC who showed tolerance to previous treatment.

Cohen86 used pembrolizumab to treat 26 adult patients with advanced carcinoma of the salivary glands. Pembrolizumab (10 mg/kg, iv) was administered once every 2 weeks for 24 months. The median duration of follow-up was 61.9 (IQR, 8.7–88.4) weeks. The ORR was 11.5%; 20.7% of patients reached 6-month PFS. A total of 70.4% patients reached 6-month OS. Also, 22 patients (84.6%) experienced treatment-related adverse events, mainly diarrhea, reduced appetite, pruritus, and fatigue. Two patients discontinued treatment because of arthritis and hepatitis, and 1 patient died of interstitial pneumonia. Their clinical trial showed that pembrolizumab had high antitumor activity and few toxic and side effects for HNC patients with carcinoma of the salivary glands at middle and advanced stages.

Nivolumab
Ferris et al40 randomly divided 361 adult patients with recurrent/metastatic HNSCC into a nivolumab group (240 cases) and standard therapy group (121 cases). The former was given nivolumab (3 mg/kg, iv) once every 2 weeks, whereas the latter was given a traditional agent (methotrexate, docetaxel, or cetuximab), and the clinical trial continued until disease progression. Responses were assessed every 6 weeks and the median duration of follow-up was 5.1 months. The ORR and PRR of the nivolumab group were 13.3% and 10.8%, and those of the standard therapy group were 5.8% and 5.0%, respectively. The median PFS of the nivolumab group was 2.0 months, and 19.7% patients reached 6-month PFS. The median PFS of the standard therapy group was 2.3 months and 9.9% patients reached 6-month PFS. The median OS of the nivolumab group was 7.5 months and 36% patients reached 1-year PFS. The median OS of the standard therapy group was 5.1 months and 16.6% patients reached 1-year PFS. Also, 139 patients in the nivolumab group experienced treatment-related adverse events (58.9%), mainly fatigue, nausea, and rash. In addition, 31 patients (13.1%) experienced treatment-related adverse events of grade >3, and 2 patients died of hypercalcemia and pneumonia, respectively. Eighty-six patients in the standard therapy group experienced treatment-related adverse events (77.5%), mainly nausea, fatigue, and anemia. Also, 39 patients (35.1%) experienced treatment-related adverse events of grade >3, and 1 patient died of pulmonary infection. The curative effect and survival period for nivolumab were more than twofold better and longer than a traditional regimen, and the number of serious adverse reactions was about one-third that of the traditional regimen.

PD-L1-targeted drugs
At present, the main PD-L1-targeted drug for HNSCC treatment is durvalumab (MEDI4736). It is a human IgG1 monoclonal antibody that blocks PD-L1 binding to its receptors and is used for recurrent/metastatic HNSCC.

Segal et al41 used durvalumab to treat 62 adult patients with recurrent/metastatic HNSCC who underwent PD-L1 immunohistochemical analyses. Overall, 40% of patients were HPV+, 39% were HPV−, and 21% of patients could not be evaluated. Durvalumab (10 mg/kg, iv) was administered once every 2 weeks for 12 months. The median duration of follow-up was 24 weeks. Among 71 evaluable patients, the ORR was 12%, whereas the response rate of PD-L1-positive patients was 25%. The 24-week disease control rate was 16% and that of PD-L1 positive patients was 25%. The prevalence of treatment-related adverse events among these patients was 60% and was mainly fatigue, diarrhea, and nausea. Also, 7% of patients suffered treatment-related adverse events of grade >3. There were no treatment-related deaths.

Fury et al41 used durvalumab to treat 50 adult patients diagnosed with recurrent/metastatic HNSCC. They were administered durvalumab (10 mg/kg, iv) once every 2 weeks for 12 months. The median duration of follow-up was 8 weeks. Among the 29 patients assessed, 7 cases (24.1%) had obvious radiographic shrinkage of target tumor lesions, whereas 5 did not have objective evidence of progression for ≥12 (IQR, 6–24) weeks. Four patients showed a partial response. For evaluable patients with a median administration dose
of 3 (IQR, 1–8) times, the prevalence of treatment-related adverse events was 39%, mainly nausea, diarrhea, dizziness, and rash. Treatment-related adverse events of grade >3 was observed in 5% of patients and was associated with increased glutamyltransferase levels. No treatment-related adverse events led to study discontinuation.

Segal42 used durvalumab to treat 151 adult patients with recurrent/metastatic HNSCC. They were given durvalumab (10 mg/kg, iv) once every 2 weeks for 12 months. Among 105 evaluable patients with a median administration dose of 3 (IQR, 1–8) times, the prevalence of treatment-related adverse events was 33%. Also, 7% of patients experienced treatment-related adverse events of grade >3, mainly fatigue, nausea, and rash.

**Conclusion**

The clinical trials mentioned above show that PD-1/PD-L1-targeted drugs have obvious advantages over traditional therapeutic regimens in terms of ORR, survival, and safety when treating recurrent/metastatic HNC. They have shown enormous potential as new types of anticancer drugs. The ORR of PD-1 as treatment of recurrent/metastatic HNC was higher than that of PD-L1. There was no significant difference between PD-1-targeted drugs and PD-L1-targeted drugs in terms of the prevalence of treatment-related adverse events. However, the prevalence of treatment-related adverse events of grade >3 by PD-1-targeted drugs was obviously higher than that observed with PD-L1-targeted drugs. We hypothesize that the reason for the differences between PD-1- and PD-L1-targeted drugs in curative effect and safety is that PD1 antibody can simultaneously block the signaling pathways between PD-1 and PD-L1 and between PD-1 and PD-L2. If the signaling pathway between PD-1 and PD-L1 is blocked, T-cell inhibition will occur and its antitumor effect will be improved. Conversely, because PD-L2 mediates immune tolerance to protect the organism, blocked signaling pathways between PD-1 and PD-L1 may cause more serious adverse events.43,44 However, PD-L1 antibody can only block the signaling pathway between PD-1 and PD-L1 and not the one between PD-L2 and PD-1. Hence, the prevalence of severe adverse events caused by PD-L1 antibody is lower than that caused by PD-1 antibody. Based on the pre-condition that the prevalence of severe adverse responses is controlled effectively, PD-1-targeted drugs have greater potential than PD-L1-targeted drugs. Among PD-1-targeted drugs, pembrolizumab has the highest ORR in HNSCC treatment and has the greatest potential among PD-1/PD-L1-targeting drugs. Pembrolizumab treatment leads to a better prognosis for HPV+ HNSCC patients than for HPV− HNSCC patients. Moreover, pembrolizumab has higher clinical activity and a lower prevalence of treatment-related adverse events for HNSCC than for salivary gland carcinoma. Therefore, pembrolizumab has the greatest potential for the treatment of HPV+ HNSCC (Table 1).

The clinical trials stated above show that, when the regimens of fixed-dose pembrolizumab (200 mg, iv, once every 3 weeks) and a dose regimen based on weight (10 mg/kg once every 2 weeks) were compared, no significant differences were found in their ORR, PFS, and overall occurrence rate of treatment-related adverse events. Although a fixed-dose regimen carries a lower OS than a dose regimen by weight, it can greatly reduce the prevalence of adverse events of grade >3 and is more acceptable to patients. This may be the reason why a fixed-dose regimen (200 mg, iv, for 30 minutes once every 3 weeks) is recommended by the FDA.

**Research prospects and expectations of PD-1/PD-L1-targeted treatment of HNC**

Exclusive application of PD-1- or PD-L1-targeted drugs has achieved groundbreaking curative effects in the treatment of recurrent/metastatic HNSCC in clinical trials and has shown enormous development prospects. Even though exclusive application of PD-1- or PD-L1-targeted drugs for the treatment of recurrent/metastatic HNSCC has been approved by the FDA, several problems remain.

The curative effect and safety of PD-1/PD-L1-targeted therapy for recurrent/metastatic HNSCC requires more clinical data. So far, data have been obtained using a single drug, such as pembrolizumab, nivolumab, or durvalumab, to treat ungrouped recurrent/metastatic HNSCC. Experiments for grouped recurrent/metastatic HNSCC using two or three drugs in combination have not been done. Pembrolizumab has the greatest potential as a PD-1-targeted drug, but its optimal dose, administration regimen, and prevalence of treatment-related adverse events of grade >3 must be discovered.

Besides recurrent/metastatic HNSCC, the curative effect and safety of PD-1/PD-L1-targeted drugs for HNSCC and HNC of other diseases in different clinical stages should be explored further. PD-1/PD-L1-targeted drugs can be immunosuppressive to the organism.20 Then, whether PD-1/PD-L1-targeted drugs have a favorable inhibitory effect on precancerous lesions and early phase or metaphase HNSCC and whether they can reduce local tumor recurrence or distant metastasis can be studied. Pembrolizumab has a favorable curative effect and safety for the treatment of advanced-stage salivary gland carcinoma,28 and EBV+ nasopharyngeal
carcinoma has high expression of PD-L1. These observations suggest that PD-1/PD-L1-targeted drugs may have good therapeutic effects in other HNC disorders, such as adenocarcinoma and nasopharyngeal carcinoma, which merits further research.

The curative effect and safety of PD-1/PD-L1-targeted drugs using a traditional regimen to treat HNSCC should be explored further. Several clinical trials have shown that PD-1/PD-L1-targeted drugs combined with radiotherapy and chemotherapy can enhance the killing of tumor cells. Hence, clinical research on PD-1/PD-L1-targeted drugs combined with traditional chemotherapeutics (docetaxel, cisplatin, and 5-fluorouracil), biotherapy (vorinostat, imlygic, and motolimod), radiotherapy (intensity-modulated radiotherapy, image-guided radiotherapy, and stereotactic body radiotherapy), and surgical treatment should be strengthened. Selection of drug doses, safety, and tolerability in combination therapy should be examined.

Also, an in-depth exploration of the curative effect and safety of PD-1/PD-L1-targeted drugs for HNSCC treatment should be carried out. PD-1/PD-L1-targeted drugs show their respective antitumor effects, but whether combined application of PD-1- and PD-L1-targeted drugs can elicit enhanced effects needs further experimental verification. Cetuximab is a monoclonal antibody of the targeted EGFR, and studies have shown that blockade of PD-1/PD-L1 signaling can improve anticancer effects. Hence, combined application of PD-1/PD-L1-targeted drugs and cetuximab may also have favorable clinical effects. Ipilimumab and tremelimumab are human-specific monoclonal antibodies that inhibit CTLA-4 expression, and studies have shown that simultaneous targeting of PD-L1 and CTLA-4 pathways generates an enhanced effect. Hence, the effect of a combined therapeutic schedule of PD-L1-targeted drugs and CTLA-4-targeted drugs merits further research.

**Acknowledgment**

We thank all the HNC patients who participated in these and other HNSCC clinical trials to improve patient care for the next generation.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


